Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. Chief Scientific Officer. MyMD Pharmaceuticals, Inc.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

SMPL

MAY 26, 2020

Last year, the investment bank Cowen estimated that the U.S. CBD industry will be worth $16 billion by 2025. fast-tracked clinical trials of GW Pharmaceuticals’ 98 percent CBD drug, Epidiolex. There haven’t been enough clinical trials and there never will be,” said Mr. Clarke, the cannabis seed collector.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

Cannabis Law Report

OCTOBER 17, 2019

billion in 2025, according to Grandview Research. Another researcher, New Frontier Data, pegged the global value of legal and illicit cannabis together at $340 billion in 2018. Banks stay away from the cannabis industry in jurisdictions where it is illegal, and sometimes where it is legal as well. Securities.

Law 40

Law Seed-To-Sale Hemp Recreational 40